• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Advances in hepatology

    Advances in hepatology

    JournalISSN 2356-6744eISSN 2314-7709

    年发文量

    研究主题

    论文(24)

    排序
    1Hepatitis C: an Overview
    Syed Manzoor Kadri, Marija Petkovic

    Hepatitis C virus (HCV) has infected approximatelly 130–170 milion individuals in the form of chronic liver infection and hepatocellular carcinoma. In the majority of patients with the increased risk for hepatocellular carcinoma the initial rearrangement is fibrosis. HCV is a bloodborne virus. The most common route of the infection are drug use, injections, unsafe health care performance, transfusion and sexual transmission. The incubation period ranges from 2 to 6 weeks in case of HCV. HCV infection is diagnosed in the process of detecting of anti-HCV antibodies and if positive, a nucleic acid test for HCV ribonucleic acid (RNA) is done. Currently, the most promising treatment agents are direct-acting antivirals (DAAs). They have shown limited viral resistance, long treatment duration and higher cost with no proven benefits in the prevention of graft reinfections in HCV individuals. In the light of the aforementioned, there is a need to a more dubious research in the quest for the effective therapeutic modalities.

    2021
    引用
    AI阅读
    加入学术空间
    2Extrahepatic Manifestations of Hepatitis C Infection
    Alberto Frosi

    Chronic infection with the hepatitis C virus (HCV) is a major cause of liver disease worldwide and is also responsible for extrahepatic manifestations (EHM) involving many different organs and apparatus: skin, salivary glands, eyes, thyroid, kidneys, peripheral and central nervous system, and immune system. Mixed cryoglobulinemia is the most frequent, best known and strictly HCV-associated EHM. A significant association between HCV and B-cell Non-Hodgkin-Lymphoma is reported although the incidence of lymphoma among HCV-infected patients overall remains low. HCV-infected patients have increased rates of insulin resistance, diabetes, and atherosclerosis, which may lead to increased cardiovascular disorders. The mechanisms causing the extrahepatic effects of HCV infection are likely multifactorial and may include endocrine effects, HCV replication in extrahepatic cells, or a heightened immune reaction with systemic effects. Because of this associations, it is suggested testing for HCV infection the patients with a clinical condition described as linked to hepatitis C. Conversely, patients diagnosed with HCV infection should have evaluation for a possible EHM. EHM of HCV can be considered an established indication for antiviral treatment with direct acting antivirals, even in the absence of overt liver disease. Successful eradication of HCV can improve and in some cases cure EHM of HCV. B cell depleting agents may be considered to be the best biological target option for patients with more severe EHM in combination with the antivirals.

    2021引用:14
    引用
    AI阅读
    加入学术空间
    3Therapy That Targets Growth Factor Receptors: Novel Approach for Liver Cirrhosis Treatment
    Halyna Kuznietsova,Olexandr Ogloblya

    The background of liver fibrous degeneration is excessive cell proliferation including hepatic stellate cells, inflammatory cells, fibroblasts and myofibroblasts. Often it is the consequence of increased growth factors and/or their receptors expression. Key contributors to the liver cell proliferation are EGFR, FGFR, PDGFR, VEGFR, TGFβR, the increased expression of which is indicated on in vitro and in vivo models of liver fibrosis and in patients who experienced fibrosis-accompanied liver diseases. Elimination of growth factors/suppression of their receptors is associated with the weakening/elimination of certain processes responsible for fibrogenesis. This chapter represents the evidences of the efficacy of growth factor receptors signaling downregulation for the suppression of liver fibrosis and cirrhosis and their individual manifestations. The data on established and experimental therapeutics – specific and multikinase growth factor receptor inhibitors which demonstrated antifibrotic and anticirrhotic activity under in vitro and in vivo models, are also presented.

    2021
    引用
    AI阅读
    加入学术空间
    4Spontaneous Bacterial Peritonitis: Physiopathological Mechanism and Clinical Manifestations
    Rebeca Pérez-Cabeza De Vaca,Balasubramaniyan Vairappan, Tomás Cortés Espinoza,Juan Antonio Suárez Cuenca,Cuauhtemoc Licona Cassani,Brenda Maldonado Arriaga, Chrisitan Navarro Gerrard, Diana Selene Morgan Penagos,Paul Mondragón Terán,Victoria Chagoya De Sanchez

    Changes in intestinal permeability have been determined to influence secondary inflammatory reactions and clinical manifestations such as spontaneous bacterial peritonitis (SBP) secondary to cirrhosis. As of yet, no in-depth exploration of the changes in the microbiota and how this influences cirrhosis to differ from clinically more severe cases than others has not begun. However, at the level of pathophysiological mechanism, it must be taken into account that due to the abuse of substances such as alcohol and chronic fatty liver disease, changes in the bacterial composition and intestinal permeability are induced. This set of changes in the bacterial composition (microbiome) and modification of the intestinal permeability could be related to the presence of ascites and spontaneous peritonitis secondary to cirrhosis, being of relevance the knowledge of the mechanisms underlying this phenomenon, as well as clinical manifestation. Prophylaxis and antibiotic treatment of SBP requires clinical knowledge for the treatment decisions based mainly on the presence of ascitic fluid, accompanied of risk factors, laboratory indexes such as PMN count and culture results, in order to determine the kind of molecule that will help to the SBP recovery or to amelioration symptoms, always taking care of not exceed the antibiotic consumption and restoring the microbiome imbalance.

    2021引用:2
    引用
    AI阅读
    加入学术空间
    5Diagnosis of Nonalcoholic Steatohepatitis
    Eira Cerda-Reyes,Alicia Sarahi Ojeda-Yuren,Julián Torres-Vazquez,María del Rosario Herrero Maceda,Martín Uriel Vázquez-Medina,Perla Denice Flores-Rangel, Yailin Fabiola Velásquez Palacios,Saraid Cerda-Reyes, Graciela Elia Castro-Narro

    The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in the last years up to 25% in the adult population. This disease includes a large spectrum of disorders, from simple fatty liver disease to cirrhosis and Hepatocellular Carcinoma (HCC), and they are related to chronic metabolic conditions. NAFLD is characterized by the presence of at least 5% of hepatic steatosis without evidence of hepatocellular injury. The diagnosis of this disease should be of exclusion and focused on its progression, treatment, and identification of the prognosis. The European Association for the Study of the Liver (EASL), the National Institute for Health and Care Excellence (NICE), the Italian Association for the Study of the Liver (AISF), and the American Association for the Study of the Liver (AASLD), published their Clinical Guidelines that have identified the criteria for the diagnosis of NAFLD, several, using imaging or histological diagnostic methods, although they imply a different approach and screening. The Fatty Liver Index and the NAFLD Liver Fat Score are used by 3 out of 5 Guidelines and they are easily calculated using blood tests and clinical information. Other non-invasive scales for NAFLD are the NAFLD fibrosis score (NFS), Fib-4, AST/ALT ratio index; also the ELF panel, Fibrometer, Fibrotest, Hepascore; and some imaging techniques that include transient elastography, magnetic resonance elastography (MRE), and shear wave elastography. Finally, proteomic’s and glycomic’s technologic biomarkers are currently under investigation and recent use, such as Cytokeratin 18 and Sirtuin 1. Still, liver biopsy remains the gold standard to distinguish between steatohepatitis and simple steatosis, using the histological classification and staging scoring systems of NAFLD Activity Score (NAS) and the Steatosis Activity Fibrosis (SAF), to evaluate the disease’s activity.

    2021
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 24 篇论文

    高被引作者

    作者引用发文
    Jiang Joy X631
    Natalie Torok631
    Hind Fallatah591
    Stanislas Pol151
    Henry LY Chan151
    Maria Buti151
    Teerha Piratvisuth151
    Ed Gane151
    Gilbert Deray151
    Antonio Craxi151

    高产作者

    作者引用发文
    Eira Cerda01
    Teerha Piratvisuth151
    Perla Denice Flores-Rangel01
    Saraid Cerda-Reyes01
    Ed Gane151
    Simona Claudia Cambrea11
    Michinori Kohara11
    Reid Lola M51
    Atsushi Fukunaga01
    Natalie Torok631

    相关期刊

    Current hepatitis reports
    Current Hepatology Reports
    Euroasian journal of hepato-gastroenterology
    Open journal of gastroenterology
    Kanzo
    Hepatic Medicine : Evidence and Research
    Viral Hepatitis Journal
    The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
    Russian Journal of Gastroenterology, Hepatology, Coloproctology
    GastroHep